Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HBV specific TCR redirected T-cell therapy - Lion TCR

Next Previous
Drug Profile

HBV specific TCR redirected T-cell therapy - Lion TCR

Alternative Names: HBV antigen specific TCR redirected T cell; LioCyx; LioCyx-M; LioCyx-M004; LT-C21; mRNA HBV/TCR T-cells; T-cell receptor directed T-cell therapy; TCR-T

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lion TCR
  • Class Antineoplastics; Antivirals; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B; Liver cancer

Most Recent Events

  • 15 Sep 2025 The US FDA clears an IND application for HBV specific TCR redirected T-cell therapy in Hepatitis B
  • 15 Sep 2025 Lion TC plans a phase I/II trial for Hepatitis B
  • 30 May 2025 Pharmacodynamics data from a phase I trial in Liver cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top